Reiner Laus, MD., President & CEO of Bavarian Nordic's US subsidiary,
BN ImmunoTherapeutics Inc., will also join the Executive Management. Reiner
Laus was previously Vice President of Research and Development at Dendreon
Corporation in Seattle, Washington where he was responsible for discovery,
pre-clinical and development functions.
Executive Management hereafter consists of the following:
Anders Hedegaard, President & CEO
Nicolai Buhl Andersen, EVP Commercial Affairs
Paul Chaplin, EVP Research & Development
Reiner Laus, EVP, and CEO of BN ImmunoTherapeutics Inc.
Morten Max Rasmussen, EVP Transactions, Legal & IPR
Anders Gram, EVP Technical Operations
Ole Larsen, EVP Finance
Annual Report 2007 The full 2007 Annual Report was published on March 31, 2008 and is available for download on the company's website: http://www.bavarian-nordic.com
About Bavarian Nordic:
Bavarian Nordic, headquartered in Denmark, is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer.
In the U.S., Bavarian Nordic operates subsidiary companies, BN ImmunoTherapeutics, in Mountain View, California developing vaccines against cancers, and Bavarian Nordic Inc. in Washington, D.C. focused on business development, marketing, and government relations for the Bavarian Nordic Group.
For more information on Bavarian Nordic visit: http://www.bavarian-nordic.com
|SOURCE Bavarian Nordic A/S|
Copyright©2008 PR Newswire.
All rights reserved